Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2014

01.08.2014 | Original Article

Vitamin D Deficiency and Corticosteroid Use Are Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease Patients

verfasst von: Bincy P. Abraham, Preethi Prasad, Hoda M. Malaty

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

As several factors can contribute to low bone mineral density (BMD), we investigated the role of vitamin D in low BMD while controlling for other risk factors in inflammatory bowel diseases (IBD) patients.

Methods

We conducted a prospective cross-sectional study between 2008 and 2012 in adult IBD patients. Demographic data including age, gender, ethnicity, BMI, along with disease type and location, vitamin D levels, prior corticosteroid use, and anti-TNF use were recorded and evaluated with DEXA results.

Results

A total of 166 patients [105 Crohn’s disease (CD), 61 ulcerative colitis (UC)] qualified for the study. Low BMD was found in 40 %, twice as frequently in CD than in UC (p = 0.048). Higher prevalence of low BMD was associated with those of male gender (p = 0.05), Asian ethnicity (p = 0.02), and history of corticosteroid use (p = 0.001). Age, body mass index, or disease location did not increase the risk of low BMD. The overall prevalence of low vitamin D was 60 %, with insufficiency (25-hydroxy levels between 20 and 30 ng/mL) found in 37 % and deficiency (levels <20 ng/mL) found in 23 % of the patients. Vitamin D insufficient and deficient patients were two times (p = 0.049) and almost 3 times (p = 0.02) as likely to have low BMD, respectively.

Conclusions

Low vitamin D, male gender, Asian ethnicity, CD, and corticosteroid use significantly increased the risk of having low BMD, while age and disease location did not affect BMD in our IBD population. It remains important to evaluate for vitamin D nutritional deficiency and limit corticosteroid use to help prevent low BMD in IBD patients.
Literatur
1.
Zurück zum Zitat Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol. 2006;101:1546–1550.PubMedCrossRef Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol. 2006;101:1546–1550.PubMedCrossRef
2.
Zurück zum Zitat Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. Ann Intern Med. 2000;133:795–799.PubMedCrossRef Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. Ann Intern Med. 2000;133:795–799.PubMedCrossRef
3.
Zurück zum Zitat Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–694.PubMedCrossRef Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–694.PubMedCrossRef
4.
Zurück zum Zitat Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483–1490.PubMedCrossRef Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483–1490.PubMedCrossRef
5.
Zurück zum Zitat Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep 2010;524–529. Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep 2010;524–529.
6.
Zurück zum Zitat Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol. 2003;98:2468–2473.PubMedCrossRef Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol. 2003;98:2468–2473.PubMedCrossRef
7.
Zurück zum Zitat Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103:1451–1459.PubMedCrossRef Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103:1451–1459.PubMedCrossRef
8.
Zurück zum Zitat Jahnsen J, Falch JA, Mowinckel P, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:192–199.PubMedCrossRef Jahnsen J, Falch JA, Mowinckel P, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:192–199.PubMedCrossRef
9.
Zurück zum Zitat Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012;91:356–363.PubMedCrossRef Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012;91:356–363.PubMedCrossRef
10.
Zurück zum Zitat Frei P, Fried M, Hungerbuhler V, et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006;73:40–46.PubMedCrossRef Frei P, Fried M, Hungerbuhler V, et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006;73:40–46.PubMedCrossRef
11.
Zurück zum Zitat Looker AC, Melton LJ 3rd, Borrud LG, et al. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int. 2012;23:1351–1360.PubMedCrossRef Looker AC, Melton LJ 3rd, Borrud LG, et al. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int. 2012;23:1351–1360.PubMedCrossRef
12.
Zurück zum Zitat Walldorf J, Krummenerl A, Engler K, et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 1/17/2013 (Epub ahead of print). Walldorf J, Krummenerl A, Engler K, et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 1/17/2013 (Epub ahead of print).
13.
Zurück zum Zitat Schmidt S, Mellström D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: a population-based study from Western Sweden. Inflamm Bowel Dis. 2009;15:1844–1850.PubMedCrossRef Schmidt S, Mellström D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: a population-based study from Western Sweden. Inflamm Bowel Dis. 2009;15:1844–1850.PubMedCrossRef
14.
Zurück zum Zitat Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn’s disease. Dig Dis Sci. 1998;43:2500–2506.PubMedCrossRef Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn’s disease. Dig Dis Sci. 1998;43:2500–2506.PubMedCrossRef
15.
Zurück zum Zitat Bobjer J, Katrinaki M, Tsatsanis C, et al. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013;8:e61466.PubMedCentralPubMedCrossRef Bobjer J, Katrinaki M, Tsatsanis C, et al. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013;8:e61466.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Tengstrand B, Hafström I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol. 2002;29:2299–2305.PubMed Tengstrand B, Hafström I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol. 2002;29:2299–2305.PubMed
17.
Zurück zum Zitat Fu YT, Chatur N, Cheong-Lee C, et al. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57:2144–2148.PubMedCrossRef Fu YT, Chatur N, Cheong-Lee C, et al. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57:2144–2148.PubMedCrossRef
18.
Zurück zum Zitat Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–265.PubMedCrossRef Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–265.PubMedCrossRef
19.
Zurück zum Zitat Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–106.PubMed Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–106.PubMed
20.
Zurück zum Zitat Hilmi I, Sunderesvaran K, Ananda V, et al. Increased fracture risk and osteoporosis not associated with vitamin D levels in Malaysian patients with inflammatory bowel disease. J Clin Endocrinol Metab. 2013;98:2415–2421.PubMedCrossRef Hilmi I, Sunderesvaran K, Ananda V, et al. Increased fracture risk and osteoporosis not associated with vitamin D levels in Malaysian patients with inflammatory bowel disease. J Clin Endocrinol Metab. 2013;98:2415–2421.PubMedCrossRef
21.
Zurück zum Zitat Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203–1208.PubMedCrossRef Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203–1208.PubMedCrossRef
22.
Zurück zum Zitat Del Carmen Navarro M, Saavedra P, Jódar E, et al. Osteoporosis and metabolic syndrome according to socio-economic status; contribution of PTH, Vitamin D and body weight: the Canarian Osteoporosis Poverty Study (COPS). Clin Endocrinol (Oxf). 2013;78:681–686.CrossRef Del Carmen Navarro M, Saavedra P, Jódar E, et al. Osteoporosis and metabolic syndrome according to socio-economic status; contribution of PTH, Vitamin D and body weight: the Canarian Osteoporosis Poverty Study (COPS). Clin Endocrinol (Oxf). 2013;78:681–686.CrossRef
23.
Zurück zum Zitat Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000;247:63–70.PubMedCrossRef Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000;247:63–70.PubMedCrossRef
24.
Zurück zum Zitat Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–153.PubMedCrossRef Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–153.PubMedCrossRef
25.
Zurück zum Zitat Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031–1039.PubMed Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031–1039.PubMed
26.
Zurück zum Zitat El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56:825–829.PubMedCrossRef El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56:825–829.PubMedCrossRef
27.
Zurück zum Zitat Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131–137.PubMedCrossRef Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131–137.PubMedCrossRef
28.
Zurück zum Zitat Kaya G, Koçak E, Akbal E, et al. Comparison of the possible risk factors of bone mineral density in subjects with ulcerative colitis and healthy subjects. South Med J. 2011;104:747–751.PubMedCrossRef Kaya G, Koçak E, Akbal E, et al. Comparison of the possible risk factors of bone mineral density in subjects with ulcerative colitis and healthy subjects. South Med J. 2011;104:747–751.PubMedCrossRef
29.
Zurück zum Zitat Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract. 2006;12:622–629.PubMedCrossRef Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract. 2006;12:622–629.PubMedCrossRef
30.
Zurück zum Zitat Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–942.PubMedCrossRef Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–942.PubMedCrossRef
31.
Zurück zum Zitat Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol. 2008;52:684–691.PubMedCrossRef Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol. 2008;52:684–691.PubMedCrossRef
32.
Zurück zum Zitat Shirazi KM, Somi MH, Rezaeifar P, et al. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012;18:241–247.PubMedCentralPubMedCrossRef Shirazi KM, Somi MH, Rezaeifar P, et al. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012;18:241–247.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition. 2011;27:1023–1028.PubMedCrossRef Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition. 2011;27:1023–1028.PubMedCrossRef
34.
Zurück zum Zitat Sivagurunathan S, Muir MM, Brennan TC, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20:390–398.PubMedCrossRef Sivagurunathan S, Muir MM, Brennan TC, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20:390–398.PubMedCrossRef
35.
Zurück zum Zitat Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041–1048.PubMedCentralPubMedCrossRef Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041–1048.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–1384.PubMedCrossRef Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–1384.PubMedCrossRef
37.
Zurück zum Zitat Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851–857.PubMedCrossRef Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851–857.PubMedCrossRef
38.
Zurück zum Zitat Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55–63.PubMedCrossRef Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55–63.PubMedCrossRef
39.
Zurück zum Zitat Veerappan SG, O’Morain CA, Daly JS, et al. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261–1272.PubMedCrossRef Veerappan SG, O’Morain CA, Daly JS, et al. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261–1272.PubMedCrossRef
40.
Zurück zum Zitat Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909–920.PubMedCrossRef Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909–920.PubMedCrossRef
41.
Zurück zum Zitat Etzel JP, Larson MF, Anawalt BD, et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;17:2122–2129.PubMedCrossRef Etzel JP, Larson MF, Anawalt BD, et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;17:2122–2129.PubMedCrossRef
Metadaten
Titel
Vitamin D Deficiency and Corticosteroid Use Are Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease Patients
verfasst von
Bincy P. Abraham
Preethi Prasad
Hoda M. Malaty
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2014
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3102-x

Weitere Artikel der Ausgabe 8/2014

Digestive Diseases and Sciences 8/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.